Nobody claims it is a drug, a cure or a treatment available in the market. But yes, it is close and very promising. I dont think we should be debating on these lines. If it was a treatment/ drug produced, it would not be trading at 1p ish...even a learning disability person would know that! What is important is the change in circumstances of the company and that is cash in and a lot coming in next 12 months. Trading occurs on sentiments but these are hard facts. Based only on the present deal only, the SP is currently miles away from where it should be. As regards trials, yes the trials go up to phase IV but phase IV is after the drug is licensed, in the market and being used so forget about them for the moment. You are only left with phase II & III clinical trials. Phase I trials are only started after successful and promising lab trials and phase 0 trials.Two Phase I trials commenced in May this year and 3 months later PRONAi jumps in to takeover the trials and future product for hundreds of millions and future royalties! There's got to be a reason or two. The success is obvious. The world of cancer research knows CHK1 is their best bet at the moment. So Well Done SAR. Furthermore, with the cash in hand SAR has never been in a better position to crack on with so many other drug molecules that they have been developing at a relatively slow pace. So please don't try de-ramping the share. Success should be recognised when it is due.
I think been referred to fast-tracked sounds like you will get a drug through in a year instead of four too many PI's been stating $88million dollars in the next 12 months when it won't be. some didnt realise we only had a 27.5% share in CHK1 and were quoting the $330m
Yes no problem it takes years but some drugs take less time than others. Having been involved in drug regulation for years I know. Maybe fast track is misleading but as an example 3 years instead of 4 is fast tracked
Estar I also like the fact we retain ownership of future compound pipeline. The patents here are overlooked and I believe this is just the start for SAR. Long time coming but I believe it will be the star performer of 2017.
Investment summary: The deal changes the outlook of Sareum Holdings Plc. Not only it does remove the ongoing cost of the clinical trial (£300k to be returned) but also generates an upfront income of $1.9m/£1.4m and the potential for future milestones and royalties. The company will use this new resource to enhance its remaining pipeline.
It wasn't meant to be patronising, but all of 'this' i.e. literally everything that 'is' SAR is my b/g & career, so forgive me if I have the compulion to respond when I read comments such as 'fast-tracking ' a drug.
I still don't think you get my point from your 'drugs can get to market quicker fact' comment, but no problem here. Ppl will believe what they want. :)
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.